Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis

Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358–74.

Article  CAS  PubMed  Google Scholar 

Platzbecker U. Treatment of MDS. Blood. 2019;133:1096–107.

Article  CAS  PubMed  Google Scholar 

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.

Article  PubMed  PubMed Central  Google Scholar 

Gagelmann N, Kröger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021? Haematologica. 2021;106:1794–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng G-S, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003–2007 versus 2013–2017 cohorts. Ann Intern Med. 2020;172:229.

Article  PubMed  PubMed Central  Google Scholar 

Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission – a review from the Acute Leukemia Working Party of the EBMT. Haematologica. 2015;100:859–69.

Article  PubMed  PubMed Central  Google Scholar 

Kröger N, Iacobelli S, Franke G-N, Platzbecker U, Uddin R, Hübel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35:2157–64.

Article  PubMed  Google Scholar 

Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.

Article  PubMed  PubMed Central  Google Scholar 

Rashidi A, Meybodi MA, Cao W, Chu H, Warlick ED, Devine S, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation in myelodysplastic syndromes: systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26:e138–41.

Article  CAS  PubMed  Google Scholar 

Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti GJ, Ciceri F, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417–28.

Article  CAS  PubMed  Google Scholar 

Aoki K, Ishikawa T, Ishiyama K, Aoki J, Itonaga H, Fukuda T, et al. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. Br J Haematol. 2015;168:463–6.

Article  PubMed  Google Scholar 

Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y. et al. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone Marrow Transplant. 2021;56:2510–7. https://doi.org/10.1038/s41409-021-01324-8.

Article  CAS  PubMed  Google Scholar 

Basu S, Sussman JB, Hayward RA. Detecting heterogeneous treatment effects to guide personalized blood pressure treatment: a modeling study of randomized clinical trials. Ann Intern Med. 2017;166:354–60.

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Tian L, Cai T, Yu M. A general statistical framework for subgroup identification and comparative treatment scoring. Biometrics. 2017;73:1199–209.

Article  PubMed  PubMed Central  Google Scholar 

VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions. Ann Intern Med. 2011;154:680–3.

Article  PubMed  Google Scholar 

Baum A, Scarpa J, Bruzelius E, Tamler R, Basu S, Faghmous J. Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. Lancet Diabetes Endocrinol. 2017;5:808–15.

Article  PubMed  PubMed Central  Google Scholar 

Huling JD, Yu M. Subgroup identification using the personalized package. J Stat Softw. 2021;98:1–60. https://doi.org/10.18637/jss.v098.i05.

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-Intensity Conditioning Regimen Workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15:367–9.

Article  PubMed  PubMed Central  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

Article  PubMed  PubMed Central  Google Scholar 

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stekhoven DJ, Bühlmann P. MissForest–non-parametric missing value imputation for mixed-type data. Bioinforma Oxf Engl. 2012;28:112–8.

Article  CAS  Google Scholar 

Waljee AK, Mukherjee A, Singal AG, Zhang Y, Warren J, Balis U, et al. Comparison of imputation methods for missing laboratory data in medicine. BMJ Open. 2013;3:e002847.

Article  PubMed  PubMed Central  Google Scholar 

Shah AD, Bartlett JW, Carpenter J, Nicholas O, Hemingway H. Comparison of random forest and parametric imputation models for imputing missing data using MICE: a CALIBER study. Am J Epidemiol. 2014;179:764–74.

Article  PubMed  PubMed Central  Google Scholar 

Slade E, Naylor MG. A fair comparison of tree-based and parametric methods in multiple imputation by chained equations. Stat Med. 2020;39:1156–66.

Article  PubMed  PubMed Central  Google Scholar 

Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M. et al. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study. JAMA Oncol. 2020;6:486–93. https://doi.org/10.1001/jamaoncol.2019.5140.

Article  PubMed  Google Scholar 

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party E. Am J Hematol. 2018;93:1142–52.

Article  PubMed  Google Scholar 

Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2020;34:87–99.

Article  CAS  PubMed  Google Scholar 

Saraceni F, Labopin M, Forcade E, Kröger N, Socié G, Niittyvuopio R, et al. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: a study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med. 2021;10:23–33.

Article  PubMed  Google Scholar 

Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525–36.

Article  CAS  PubMed  Google Scholar 

Konuma T, Kondo T, Mizuno S, Doki N, Aoki J, Fukuda T, et al. Conditioning intensity for allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with poor-prognosis cytogenetics in first complete remission. Biol Blood Marrow Transplant. 2020;26:463–71.

Article  CAS  PubMed  Google Scholar 

Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, et al. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 2018;32:1787–94.

Article  PubMed  Google Scholar 

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273–83.

Article  CAS  PubMed  Google Scholar 

Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, et al. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2015;50:1063–8.

Article  CAS  PubMed  Google Scholar 

Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114–25.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif